A Clinical Trial Comparing the Immunogenicity of Recombinant New Coronavirus Vaccine (CHO Cells) Among People Aged 3 to 17 and 18 to 59 Years of Age
Latest Information Update: 27 Apr 2023
At a glance
- Drugs ZF 2001 (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Anhui Zhifei Longcom Biopharmaceutical
- 23 Apr 2023 Status changed from recruiting to completed.
- 11 Nov 2021 New trial record